Valbenazine shows promise for easing involuntary movements in tardive dyskinesia
NCT ID NCT05859698
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 4 study tested valbenazine in 59 adults with tardive dyskinesia (involuntary muscle movements) caused by psychiatric medications. Participants had schizophrenia, bipolar disorder, or major depression. Over 24 weeks, researchers measured changes in quality of life, daily functioning, and overall health using patient and clinician reports. The goal was to see if valbenazine reduces the impact of these movements on everyday life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
valbenazine
What this could lead to
If successful, valbenazine could offer a well-tolerated option to reduce the impact of tardive dyskinesia on daily life and emotional well-being.
What could go wrong
This is a small, single-arm, open-label study with no placebo group, so results may be less reliable. Tardive dyskinesia can be persistent, and not everyone may respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TARDIVE DYSKINESIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Neurocrine Clinical Site
Bryant, Arkansas, 72022, United States
-
Neurocrine Clinical Site
Anaheim, California, 92805, United States
-
Neurocrine Clinical Site
Orange, California, 92868, United States
-
Neurocrine Clinical Site
Torrance, California, 90504, United States
-
Neurocrine Clinical Site
Bonita Springs, Florida, 34134, United States
-
Neurocrine Clinical Site
Miami, Florida, 33176, United States
-
Neurocrine Clinical Site
Miami Lakes, Florida, 33016, United States
-
Neurocrine Clinical Site
Okeechobee, Florida, 34972, United States
-
Neurocrine Clinical Site
Tampa, Florida, 33629, United States
-
Neurocrine Clinical Site
Atlanta, Georgia, 30328, United States
-
Neurocrine Clinical Site
Augusta, Georgia, 30912, United States
-
Neurocrine Clinical Site
Marietta, Georgia, 30060, United States
-
Neurocrine Clinical Site
Lincoln, Nebraska, 68526, United States
-
Neurocrine Clinical Site
Beechwood, Ohio, 44122, United States
-
Neurocrine Clinical Site
Oklahoma City, Oklahoma, 73112, United States
-
Neurocrine Clinical Site
DeSoto, Texas, 75115, United States
-
Neurocrine Clinical Site
El Paso, Texas, 79902, United States
-
Neurocrine Clinical Site
Houston, Texas, 77030, United States